Post IPO investors in Massachusetts, United States
Updated 16 Nov 2026
Venture funds
1 funds, by portfolio companies funded in the last 12 months| # | Fund | Sectors | Stages | Leads | Funded, 12 months |
|---|---|---|---|---|---|
| 1 | Founder Collective Founder Collective backs seed-stage startups, with recent investments including Baselayer, WHOOP and Ownwell. Cambridge, United States |
Artificial intelligence, Commerce | Seed, Early stage venture, Late stage venture | 6% | 5 |
Table 1. Post IPO investors in Massachusetts, United States: venture capital and micro VC funds ranked by companies whose most recent round closed in the last 12 months. Leads is the share of all recorded investments where the fund was lead investor. Source: FundingWatcher. Data as of 16 November 2026.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Investor | Type | Location | Phone | |
|---|---|---|---|---|
| Atlas Venture | Venture capital firm | Cambridge, United States | •••@atlasventure.com | 857 20••• |
| RA Capital Management | Startup incubator | Boston, United States | •••@racap.com | 617.77••• |
| Founder Collective | Venture capital firm | Cambridge, United States | •••@foundercollective.com | (617) ••• |
| Highland Capital Partners | Venture capital firm | Lexington, United States | •••@hcp.com | (781) ••• |
| North Bridge Venture Partners & Growth Equity | Venture capital firm | Wellesley, United States | •••@northbridge.com | 781.29••• |
| SV Health Investors | Private equity firm | Boston, United States | •••@svlsa.com | +1 617••• |
| HarbourVest Partners | Private equity firm | Boston, United States | •••@harbourvest.com | +1 617••• |
| Advent International | Private equity firm | Boston, United States | •••@adventinternational.com | 212 81••• |
8 rows of the CSV in 5 of its 15 columns, email and phone masked.
| Firm | Person | Title | Verified email | |
|---|---|---|---|---|
| Atlas Venture | B••• B••• | Partner | b•••@atlasventure.com | In the CSV |
| RA Capital Management | P••• K••• | Managing Partner | p•••@racap.com | In the CSV |
| Founder Collective | A••• H••• | General Partner | a•••@foundercollective.com | In the CSV |
| Highland Capital Partners | C••• D••• | Co-Founder & Managing Partner | c•••@hcp.com | In the CSV |
| North Bridge Venture Partners & Growth Equity | R••• D••• | General Partner | r•••@northbridge.com | In the CSV |
5 verified partner contact rows from organizations on this list, names and emails masked.
- 29 of the 48 post ipo investors in Massachusetts, United States have a published email address, 35 a phone number and 46 a website.
- Atlas Venture has the most recorded investments, 638, 179 of them as lead investor.
- 13 of them are investors in at least one company that closed its most recent round in the last 12 months.
- RA Capital Management is an investor in 9 of those companies, more than any other investor on this list.
- The newest round among their portfolio companies is Delix Therapeutics' $100.0M Series C on 9 November 2026.
- Software is the most common sector across their 531 portfolio companies (69%).
- Early stage venture is the most common investment stage, recorded for 46 of them (96%).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Post IPO investors in Massachusetts, United States
30 of 48, most investments first| # | Investor | Type | Location | Invests in | Latest portfolio companies | Funded, 12 months | Investments | Lead | Exits | Phone | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Atlas Venture | Venture capital firm | Cambridge, United States | Health care, Biotech | Diagonal Therapeutics | 1 | 638 | 179 | 199 | •••@atlasventure.com | 857 20••• | In the CSV |
| 2 | Fidelity | Investment bank | Boston, United States | Health care, Hardware | Zipline International, Tenstorrent, SiMa.ai | 7 | 586 | 178 | 285 | +1-866••• | In the CSV | |
| 3 | RA Capital Management | Startup incubator, Private equity firm | Boston, United States | Health care, Biotech | Delix Therapeutics, Superluminal Medicines, Claris Biotherapeutics | 9 | 544 | 183 | 243 | •••@racap.com | 617.77••• | In the CSV |
| 4 | Founder Collective | Venture capital firm | Cambridge, United States | Artificial intelligence, Commerce | Baselayer, WHOOP, Ownwell | 5 | 543 | 35 | 161 | •••@foundercollective.com | (617) ••• | In the CSV |
| 5 | Highland Capital Partners | Venture capital firm | Lexington, United States | Hardware, Commerce | Tomorrow.io | 1 | 507 | 157 | 154 | •••@hcp.com | (781) ••• | In the CSV |
| 6 | North Bridge Venture Partners & Growth Equity | Venture capital firm | Wellesley, United States | Hardware, Commerce | Clothia, Ravel Law, Oracle Dyn | 425 | 134 | 120 | •••@northbridge.com | 781.29••• | In the CSV | |
| 7 | SV Health Investors | Private equity firm, Venture capital firm | Boston, United States | Health care, Biotech | Alchemab Therapeutics | 1 | 325 | 76 | 95 | •••@svlsa.com | +1 617••• | In the CSV |
| 8 | TA Associates | Private equity firm | Boston, United States | Hardware, Artificial intelligence | Wunder Mobility, Stackline, Thinkproject | 317 | 173 | 194 | +1.617••• | In the CSV | ||
| 9 | Flagship Pioneering | Venture capital firm | Cambridge, United States | Biotech, Health care | Inari, Prologue Medicines, Quotient Therapeutics | 288 | 104 | 72 | 617-86••• | In the CSV | ||
| 10 | Cormorant Asset Management | Hedge fund | Boston, United States | Health care, Biotech | Triveni Bio, Third Arc Bio, BlossomHill Therapeutics | 4 | 276 | 58 | 141 | In the CSV | ||
| 11 | HarbourVest Partners | Private equity firm | Boston, United States | Fintech, Hardware | Varo Bank | 1 | 273 | 52 | 147 | •••@harbourvest.com | +1 617••• | In the CSV |
| 12 | Advent International | Private equity firm | Boston, United States | Fintech, Hardware | Coralogix, KreditBee | 2 | 234 | 97 | 89 | •••@adventinternational.com | 212 81••• | In the CSV |
| 13 | SR One | Venture capital firm | Cambridge, United States | Biotech, Health care | Asceneuron | 214 | 69 | 69 | (610) ••• | In the CSV | ||
| 14 | Bain Capital | Private equity firm, Venture capital firm | Boston, United States | Fintech, Hardware | Mintlify | 1 | 198 | 89 | 89 | •••@baincapital.com | +1 617••• | In the CSV |
| 15 | Omega Funds | Secondary purchaser, Venture capital firm | Boston, United States | Biotech, Health care | FoRx Therapeutics | 1 | 161 | 37 | 75 | •••@omegafunds.net | In the CSV | |
| 16 | Adage Capital Management | Government investment office | Boston, United States | Artificial intelligence, Health care | Welldoc | 161 | 13 | 119 | •••@adagecapital.com | 617-86••• | In the CSV | |
| 17 | Third Rock Ventures | Venture capital firm | Boston, United States | Biotech, Health care | Terremoto Biosciences | 1 | 154 | 69 | 44 | •••@thirdrockventures.com | (415) ••• | In the CSV |
| 18 | HLM Venture Partners | Venture capital firm | Boston, United States | Health care, Hardware | ArroHealth, PatientPop, ClearDATA | 138 | 41 | 51 | •••@hlmvp.com | 617-26••• | In the CSV | |
| 19 | Trustbridge Partners | Private equity firm | Boston, United States | Education, Commerce | Hope Medicine, Zilliz, huoban.com | 122 | 44 | 21 | •••@trustbridgepartners.com | In the CSV | ||
| 20 | Eastward Capital Partners | Venture debt fund | West Newton, United States | Hardware, Artificial intelligence | STRIVE, IntelyCare, Crayon | 122 | 9 | 48 | •••@eastwardcp.com | 617-96••• | In the CSV | |
| 21 | Sanofi Ventures | Corporate venture arm | Cambridge, United States | Biotech, Health care | i2o Therapeutics, Tisento Therapeutics, NGI | 119 | 31 | 28 | •••@gmail.com | +1 617••• | In the CSV | |
| 22 | Johnson & Johnson Innovation | Corporate venture arm | Cambridge, United States | Health care, Biotech | ONL Therapeutics, Flindr Therapeutics, Asgard Therapeutics | 118 | 39 | 26 | In the CSV | |||
| 23 | RockPort Capital | Venture capital firm | Boston, United States | Hardware, Biotech | NewLeaf Symbiotics, EcoFactor, Gazelle | 108 | 25 | 26 | 415-78••• | In the CSV | ||
| 24 | Atreides Management | Hedge fund, Venture capital firm | Boston, United States | Hardware, Cybersecurity | DustPhotonics, Chain Reaction | 89 | 15 | 9 | •••@atreidesmgmt.com | 617-42••• | In the CSV | |
| 25 | Eventide | Private equity firm, Venture capital firm | Boston, United States | 64 | 14 | 36 | •••@eventidefunds.com | +1-877••• | In the CSV | |||
| 26 | JDRF T1D Fund | Venture capital firm | Boston, United States | Biotech, Health care | i2o Therapeutics | 54 | 13 | 14 | •••@jdrf.org | 212-68••• | In the CSV | |
| 27 | Agent Capital | Venture capital firm | Waltham, United States | Health care, Biotech | Foresight Diagnostics, āshibio, Cyrus Biotechnology | 54 | 5 | 17 | •••@agentcapital.com | 844-69••• | In the CSV | |
| 28 | K2 HealthVentures | Private equity firm, Venture capital firm | Boston, United States | Biotech, Health care | Click Therapeutics | 1 | 51 | 28 | 24 | •••@k2hv.com | In the CSV | |
| 29 | Material Impact | Venture capital firm | Boston, United States | Biotech, Hardware | Actnano, Tierra Biosciences, Talus Renewables | 45 | 22 | 3 | In the CSV | |||
| 30 | PAR Capital Management | Venture capital firm | Boston, United States | Software | Journera, Routehappy | 39 | 9 | 11 | •••@parcapital.com | (617) ••• | In the CSV |
Table 2. Post IPO investors in Massachusetts, United States: the first 30 by recorded investments with a website and a location. Email and phone are masked here and complete in the CSV. Source: FundingWatcher. Data as of 16 November 2026. Base: 48.
Most active in the last 12 months
By portfolio companies funded| # | Investor | Location | Funded, 12 months | Portfolio | Latest |
|---|---|---|---|---|---|
| 1 | RA Capital Management | Boston, United States | 9 | 47 | Delix Therapeutics, Superluminal Medicines, Claris Biotherapeutics |
| 2 | Fidelity | Boston, United States | 7 | 40 | Zipline International, Tenstorrent, SiMa.ai |
| 3 | Founder Collective | Cambridge, United States | 5 | 119 | Baselayer, WHOOP, Ownwell |
| 4 | Cormorant Asset Management | Boston, United States | 4 | 13 | Triveni Bio, Third Arc Bio, BlossomHill Therapeutics |
| 5 | Advent International | Boston, United States | 2 | 17 | Coralogix, KreditBee |
| 6 | SV Health Investors | Boston, United States | 1 | 9 | Alchemab Therapeutics |
| 7 | Highland Capital Partners | Lexington, United States | 1 | 47 | Tomorrow.io |
| 8 | Third Rock Ventures | Boston, United States | 1 | 5 | Terremoto Biosciences |
| 9 | Bain Capital | Boston, United States | 1 | 27 | Mintlify |
| 10 | K2 HealthVentures | Boston, United States | 1 | 1 | Click Therapeutics |
| 11 | HarbourVest Partners | Boston, United States | 1 | 19 | Varo Bank |
| 12 | Atlas Venture | Cambridge, United States | 1 | 47 | Diagonal Therapeutics |
| 13 | Omega Funds | Boston, United States | 1 | 11 | FoRx Therapeutics |
Table 3. Post IPO investors in Massachusetts, United States: investors in the most companies whose most recent round falls in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Latest rounds in their portfolios
Newest first| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors on this list | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Delix Therapeutics | Delix Therapeutics develops psychoplastogen therapies that promote neuroplasticity. | Biotech | Boston, United States | Series C | $100.0M | 2026-11-09 | $244.1M | RA Capital Management | 11 to 50 | 2019 |
| Zipline International Unicorn | Zipline designs, manufactures, and operates drones that deliver medical products. | Hardware | South San Francisco, United States | Series I | $1.5B | 2026-11-05 | $3.6B | Fidelity | 1,001 to 5,000 | 2011 |
| Tenstorrent Unicorn | Tenstorrent develops AI processors and software for machine learning and data-intensive workloads. | Artificial intelligence | Santa Clara, United States | Series E | $1.5B | 2026-10-19 | $2.5B | Fidelity | 501 to 1,000 | 2016 |
| SiMa.ai | SiMa.ai develops hardware and software for deploying physical AI applications at the edge. | Artificial intelligence | San Jose, United States | Series C | $150.0M | 2026-09-28 | $505.0M | Fidelity | 101 to 250 | 2018 |
| Baselayer | Baselayer automates risk assessment and fraud detection for financial and government institutions. | Artificial intelligence | New York, United States | Series A | $35.0M | 2026-09-22 | $82.0M | Founder Collective | 51 to 100 | 2024 |
| Superluminal Medicines | Superluminal Medicines develops small-molecule therapeutics by combining AI, biology, and chemistry. | Artificial intelligence | Boston, United States | Series B | $65.5M | 2026-09-03 | $223.5M | RA Capital Management | 11 to 50 | 2022 |
| Claris Biotherapeutics | Claris Biotherapeutics develops biologic therapies for corneal diseases and ocular surface disorders. | Biotech | Jersey City, United States | Series B | $118.0M | 2026-07-28 | $225.1M | RA Capital Management | 1 to 10 | 2018 |
| Alchemab Therapeutics | Alchemab Therapeutics develops protective antibodies to prevent hard-to-treat diseases. | Biotech | London, United Kingdom | Series A | $33.6M | 2026-07-09 | $151.1M | RA Capital Management, SV Health Investors | 51 to 100 | 2019 |
| Triveni Bio | Triveni Bio develops antibody-based therapeutics for immunological and inflammatory diseases. | Biotech | Watertown, United States | Series C | $65.0M | 2026-06-17 | $272.0M | Cormorant Asset Management | 11 to 50 | 2019 |
| Element Biosciences Unicorn | Element Biosciences develops genomic sequencing and multiomics technologies for drug discovery and diagnostic applications. | Biotech | San Diego, United States | Series E | $277.0M | 2026-06-09 | $678.0M | Fidelity, RA Capital Management | 251 to 500 | 2017 |
Table 4. Post IPO investors in Massachusetts, United States: the 10 most recent rounds of companies they back. Source: FundingWatcher. Data as of 16 November 2026.
Portfolio sectors
| Portfolio sectors | Companies | Share |
|---|---|---|
| Software | 366 | 69% |
| Health care | 139 | 26% |
| Biotech | 107 | 20% |
| Hardware | 104 | 20% |
| Artificial intelligence | 76 | 14% |
| Commerce | 60 | 11% |
| Fintech | 52 | 10% |
| Cybersecurity | 36 | 7% |
| Education | 20 | 4% |
| Energy | 8 | 2% |
Table 5. Post IPO investors in Massachusetts, United States: portfolio companies by sector. Source: FundingWatcher. Data as of 16 November 2026.
Investment stages
| Investment stages | Investors | Share |
|---|---|---|
| Post IPO investors | 48 | 100% |
| Early stage investors | 46 | 96% |
| Late stage investors | 40 | 83% |
| Venture investors | 28 | 58% |
| Private equity investors | 27 | 56% |
| Seed investors | 25 | 52% |
| Debt investors | 17 | 35% |
| Convertible note investors | 7 | 15% |
Table 6. Post IPO investors in Massachusetts, United States by stage they invest at. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Investors | Share |
|---|---|---|
| Boston | 33 | 69% |
| Cambridge | 9 | 19% |
| Wellesley | 2 | 4% |
| Lexington | 1 | 2% |
| West Newton | 1 | 2% |
| Waltham | 1 | 2% |
| Springfield | 1 | 2% |
Table 7. Post IPO investors in Massachusetts, United States by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Founded
| Founded | Investors | Share |
|---|---|---|
| 2020s | 1 | 2% |
| 2010s | 14 | 32% |
| 2000s | 9 | 20% |
| 1990s | 7 | 16% |
| 1980s | 9 | 20% |
| 1970s | 1 | 2% |
Table 8. Post IPO investors in Massachusetts, United States by founding decade. Source: FundingWatcher. Data as of 16 November 2026.
Method
- An investor is on this list when its recorded investment stages include post ipo investors and its headquarters is in Massachusetts, United States. On 16 November 2026 that is 48 investors.
- 29 rows carry an email address and 35 a phone number from the investor file. Investments, lead investments and exits are the counts the source records.
- The table prints the first 30 rows by recorded investments that carry a website and a location, with email and phone masked. The CSV carries all 48 rows: 2 have no website and 0 no location.
Sources, fields and exclusions of both files: Method.
Questions
- How many post ipo investors in Massachusetts, United States are on the list?
- 48, in the file dated 16 November 2026. 13 of them invested in a company whose most recent round falls in the last 12 months.
- How many have an email address?
- 29 of the 48 carry an email address in the download and 35 a phone number.
- What does the CSV contain?
- One row per investor, 15 columns: name, types, stages, city, region, country, founded, website, linkedin, investments, funded_last_12m, exits, lead_investments, email, phone.
- How much does the list cost?
- $29 one-time for all 48 rows, no account. Every investor and every startup, two files, cost $99. With partner contacts, up to 2 per firm compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV with 48 rows, 29 firm email addresses and 35 phone numbers, on the page after payment and by mail. The emails are the address a firm publishes: 18 of the 29 are inboxes such as info@ or contact@. No partner names.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.